Selective TYROBP stabilization and SYK pathway activation to maintain neuroprotective signaling downstream of TREM2
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["TREM2 Receptor Activation Amyloid and Lipid Ligand Binding"]
B["TYROBP DAP12 Adaptor Protein Plasma Membrane TREM2 Anchoring"]
C["ITAM Phosphorylation SYK Kinase Recruitment"]
D["SYK Downstream Signaling PLCgamma PI3K Akt Cascade"]
E["Microglial Survival Phagocytosis Lipid Metabolism Program"]
F["AD ALS Pathology Reduces TYROBP Signaling Scaffold Destabilized"]
G["Selective TYROBP Stabilization Protein Stability Enhancement Strategy"]
H["SYK Activity Maintained Neuroprotective Signaling Restored"]
A --> B
B --> C
C --> D
D --> E
F -.->|"disrupts"| B
G --> B
G --> H
H --> E
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMID5 mediumValidation: 40%5 supporting / 2 opposing
✓For(5)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
2
MECH 4CLIN 1GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TREM2 drives microglia response to amyloid-β via S…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-06 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Based on the information gathered about TREM2, its protein interactions, and pathways, I'll now generate novel therapeutic hypotheses for targeting TREM2 in Alzheimer's disease following the INVOKE-2 failure:
Novel Therapeutic Hypotheses for TREM2 in Alzheimer's Disease
Hypothesis 1: TYROBP-SYK Pathway Enhancement
Title: Selective TYROBP stabilization to bypass TREM2 ectodomain loss
Description: Given TREM2's obligate partnership with TYROBP (DAP12) for signaling, developing small molecule stabilizers of the TYROBP-SYK complex could maintain downstream neuroprotective signali
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
I'll critically evaluate each of these TREM2 therapeutic hypotheses by examining their weaknesses, counter-evidence, and proposing falsifying experiments.
Critical Evaluation of TREM2 Therapeutic Hypotheses
Hypothesis 1: TYROBP-SYK Pathway Enhancement
Specific Weaknesses:
Assumes TYROBP-SYK signaling is universally beneficial, ignoring potential inflammatory consequences
Overlooks that TYROBP is shared with multiple immune receptors (not TREM2-specific)
No consideration of dose-response relationships or therapeutic window
Counter-evidence: The literature shows that exce
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Based on my analysis of the therapeutic hypotheses and available clinical data, here's my practical feasibility assessment:
PRACTICAL FEASIBILITY ASSESSMENT
HYPOTHESIS 1: TYROBP-SYK PATHWAY ENHANCEMENT
Druggability: MODERATE
Existing compounds: Fostamatinib (SYK inhibitor, FDA-approved for ITP)
Chemical matter: Multiple SYK inhibitors exist (fostamatinib, entospletinib, TAK-659)
Target validation: Strong - SYK is highly druggable kinase with validated inhibitors
Competitive Landscape:
Rigel Pharmaceuticals (fostamatinib) - established SYK franchise
M
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Based on the comprehensive debate between the Theorist, Skeptic, and Expert, I'll synthesize their inputs and produce final scored rankings. Let me analyze the evidence and score each hypothesis across the 10 dimensions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF primary murine microglia are treated with a TYROBP stabilizer (e.g., small molecule or viral TYROBP overexpression) for 48 hours, THEN phospho-SYK (p-SYK) levels will increase by at least 50% compared to vehicle-treated controls, using cultured primary microglia isolated from adult C57BL/6 mice.
pendingconf: 0.75
Expected outcome: Increased SYK phosphorylation (p-SYK/total SYK ratio) as measured by western blot or phospho-flow cytometry, along with upregulated expression of downstream neuroprotective markers (e.g., TREM2 target genes, anti-inflammatory cytokines IL-10, TGF-β)
Falsified by: No significant increase in p-SYK levels (<20% change) or downstream neuroprotective marker expression despite confirmed TYROBP stabilization would DISPROVE the hypothesis that TYROBP stabilization activates the SYK pathway for neuroprotection
Method: Primary microglia cultured from adult mice will be treated with TYROBP stabilizer or control. SYK phosphorylation will be assessed by western blot (phospho-SYK Y525/526 antibody) and multiplex qPCR will measure TREM2-regulated neuroprotective gene signatures at 48-hour endpoint.
IF 5xFAD amyloid mice (3 months old) receive intracranial AAV-mediated TYROBP overexpression in hippocampus for 8 weeks, THEN amyloid plaque-associated microglia will show enhanced SYK activation and reduced neurotoxic marker expression (iNOS, IL-1β) compared to AAV-GFP controls, using the 5xFAD mouse model of Alzheimer's disease pathology.
pendingconf: 0.72
Expected outcome: Increased p-SYK intensity in Iba1+ plaque-associated microglia (measured by immunohistochemistry quantification) and decreased pro-inflammatory gene expression (iNOS, IL-1β, TNF-α) in microglial populations isolated by MACS from treated vs control mice
Falsified by: No increase in microglial p-SYK at amyloid plaques OR no reduction in neurotoxic markers despite confirmed TYROBP overexpression would DISPROVE the hypothesis that TYROBP-SYK enhancement maintains neuroprotective signaling in disease context
Method: Bilateral hippocampal AAV9 injection for TYROBP or GFP control in 3-month-old 5xFAD mice. After 8 weeks, brain tissue will be analyzed by immunofluorescence for p-SYK (Y525/526) colocalization with Iba1+ microglia at Thioflavin-S+ plaques. qRT-PCR on FAC-sorted CD11b+ microglia for inflammatory gene panel.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
['TYROBP' — Search for structure
Click to search RCSB PDB